Organisation paid for research Program year 2022 Source: CMS Open Payments

Scora Network LLC

Neither a doctor nor a teaching hospital

Research payments

$197,876

24 payments

Through program year 2022, Scora Network LLC is reported as receiving $197,876 in research payments, across 24 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$2,500	1
2021	Research	$46,097	4
2020	Research	$48,708	4
2019	Research	$100,571	15

Breakdown

Who paid Research payments · program years 2019–2022

Eli Lilly and Company $163,761 6 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $14,504 1 payment
Spectrum Pharmaceuticals Inc. $6,330 4 payments
F. Hoffmann-La Roche AG $5,712 3 payments
Secura Bio, Inc. $2,500 1 payment
E.R. Squibb & Sons, L.L.C. $2,150 1 payment
Pfizer Inc. $1,545 7 payments
Taiho Oncology, Inc. $1,373 1 payment

Studies the money was for Research payments · program years 2019–2022

A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab VS. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression $110,047 3 payments
A Randomized Phase 2 Trial of Am0010 in Combination With Nivolumab VS. Nivolumab Alone As Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of Pd-L1 $53,715 3 payments
Afatinib in elderly EGFR M & NSCLC $14,504 1 payment
All Comers SSF $5,712 3 payments
Spi-Gcf-302 $4,472 3 payments
Clbh589d2222 $2,500 1 payment
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy $2,150 1 payment
Spi-Poz-101 $1,858 1 payment
Taiho TAS 102 Gastric Cancer TAGS $1,373 1 payment
A Phase 3 Openlabel Randomized Parallel2armmulticenter Study of Talazoparibbmn 673 Versus Physicians Choice in Germline Brca Mutation Subjects With Locally Advanced Andor Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease $870 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.